Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# Amphera

Empowering dendritic cells

## Sitemaps

- [XML Sitemap](https://www.amphera.nl/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Results REACTIVE-2 clinical trial in metastatic pancreatic cancer published in Nature Communications](https://www.amphera.nl/results-reactive-2-clinical-trial-in-metastatic-pancreatic-cancer-published-in-nature-communications/) - Amphera is pleased to announce that the results of the REACTIVE-2 trial in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) following standard of care chemotherapy have been published in Nature Communications. The REACtiVe-2 trial evaluated the safety, tolerability and immunological effects of MesoPher cell therapy in combination with CD40 agonist mitazalimab, developed by Alligator Bioscience.
- [MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMA](https://www.amphera.nl/mesopher-cell-therapy-increases-2-year-rfs-rate-in-resected-pancreatic-cancer-by-50-amphera-announces-publication-of-phase-ii-results-in-journal-of-clinical-oncology-and-orphan-designation-granted-by/) - ‘s-HERTOGENBOSCH, the Netherlands; September 25, 2024. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces publication of the results of a phase II trial in resected pancreatic cancer (REACTIVE) in the Journal of Clinical Oncology (JCO). Highlights from the REACTIVE trial in resected pancreatic cancer: The phase II trial, including
- [Amphera announces results of randomized phase II/III trial with MesoPher cell therapy in pleural mesothelioma, published in The Lancet Oncology](https://www.amphera.nl/amphera-announces-results-of-randomized-phase-ii-iii-trial-with-mesopher-cell-therapy-in-pleural-mesothelioma-published-in-the-lancet-oncology/) - Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces publication of the results of the phase II/III trial in pleural mesothelioma (DENIM) in The Lancet Oncology, one of the world’s leading scientific journals. Highlights from the DENIM trial in pleural mesothelioma: In the DENIM phase II/III trial, mesothelioma patients
- [Positive results of phase II trial with MesoPher cell therapy in resected pancreatic cancer published in the Journal of Clinical Oncology](https://www.amphera.nl/positive-results-of-phase-ii-trial-with-mesopher-cell-therapy-in-resected-pancreatic-cancer-published-in-the-journal-of-clinical-oncology/) - Amphera announces publication of the positive results of the phase II trial in resected pancreatic cancer (REACTIVE) in the Journal of Clinical Oncology (ASCO), one of the world's leading scientific journals. The conclusion of the article: "This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment
- [New video on results of Reactive phase II trial from Stichting Support Casper](https://www.amphera.nl/new-video-on-results-of-reactive-phase-ii-trial-from-stichting-support-casper/) - Stichting Support Casper has published an interesting video on the results of the Reactive clinical phase II trial in resected pancreactic cancer (Dutch language).
- [MesoPher showed promising survival in peritoneal mesothelioma](https://www.amphera.nl/mesopher-showed-promising-survival-in-peritoneal-mesothelioma/) - Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, reports publication of the positive results of the phase II study of MesoPher in peritoneal mesothelioma (MESOPEC) in the Journal for ImmunoTherapy of Cancer. Peritoneal mesothelioma is an aggressive cancer with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
- [Amphera announces a positive opinion of the European Medicines Agency on the granting of orphan medicinal product designation for MesoPher in pancreatic cancer](https://www.amphera.nl/amphera-announces-a-positive-opinion-of-the-european-medicines-agency-on-the-granting-of-orphan-medicinal-product-designation-for-mesopher-in-pancreatic-cancer/) - S-HERTOGENBOSCH, the Netherlands; June 5, 2023. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces that the EMA Committee for Orphan Medicinal Products (COMP) has recommended the granting of orphan medicinal product designation for MesoPher in pancreatic cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a
- [Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer](https://www.amphera.nl/alligator-bioscience-amphera-announce-last-patient-treated-in-mitazalimab-mesopher-reactive-2-phase-1-study-in-pancreatic-cancer/) - REACTIVE-2 is assessing the safety and immunological effect of mitazalimab in combination with MesoPher in metastatic pancreatic cancer Mitazalimab and MesoPher have both achieved positive results in separate Phase 2 clinical studies in pancreatic cancer Preliminary results of REACTIVE-2 are expected in Q4 2023 Lund, Sweden, and 's-Hertogenbosch, the Netherlands, April 26, 2023 - Alligator
- [Amphera announces clinical updates of MesoPher cell therapy](https://www.amphera.nl/amphera-announces-clinical-updates-of-mesopher-cell-therapy/) - In the phase II Reactive trial in patients with resected pancreatic cancer, MesoPher demonstrated a statistically significant 2-year Recurrence Free Survival of 60% and an excellent safety profileThe observed safety and statistically significant efficacy are the foundation for further randomized clinical research with MesoPher in pancreatic cancerThe randomized phase II/III DENIM trial in mesothelioma patients
- [Article on the Reactive study in resected pancreatic cancer published in Data in Brief](https://www.amphera.nl/article-on-the-reactive-study-in-resected-pancreatic-cancer-published-in-data-in-brief/) - Amphera is happy to announce that an article on the Reactive phase II trial in resected pancreatic cancer has been published in Data In Brief. The article describes a dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue.
- [Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022](https://www.amphera.nl/article-on-the-results-of-phase-i-ii-study-with-mesopher-in-resected-pancreatic-cancer-published-in-mednous-june-2022/) - Amphera is happy to announce that an article on the results of our phase II study with MesoPher in resected pancreatic cancer has been published in MedNous in June 2022. 2022-06 MedNous Cell therapy shows promise in pancreatic cancer
- [Last patient completed follow-up period in Phase II/III study of Amphera's MesoPher cell therapy in mesothelioma](https://www.amphera.nl/last-patient-completed-follow-up-period-in-phase-ii-iii-study-of-mesopher-cell-therapy-in-mesothelioma/) - Topline results expected early Q4 2022 `s-Hertogenbosch, The Netherlands; August 1, 2022. Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of MesoPher cell therapy to treat pleural mesothelioma. Ilona Enninga PhD, COO of Amphera said:
- [Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer](https://www.amphera.nl/ampheras-mesopher-cell-therapy-demonstrates-favourable-safety-and-promising-survival-in-a-phase-ii-clinical-trial-in-resected-pancreatic-cancer/) - Positive results from first cohort of 10 patients from REACtiVe study published in European Journal of Cancer `s-Hertogenbosch, The Netherlands; May 4, 2022. Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Amphera’s MesoPher dendritic cell therapy. Patients, with resected pancreatic cancer who had
- [First patient enrolled in ENSURE study in resected mesothelioma](https://www.amphera.nl/first-patient-enrolled-in-ensure-study-in-resected-mesothelioma/) - The ENSURE open label phase II trial (dENdritic cell therapy combined with SURgEry in mesothelioma) has enrolled the first patient. The objective of the study is to assess whether (neo)-adjuvant MesoPher dendritic cell therapy is feasible in resectable epithelioid pleural mesothelioma patients after first-line chemotherapy. The investigator initiated trial (link) will be performed at Erasmus
- [Amphera progresses two pancreatic cancer programmes after encouraging initial safety and efficacy data in mesothelioma](https://www.amphera.nl/amphera-progresses-two-pancreatic-cancer-programmes-after-encouraging-initial-safety-and-efficacy-data-in-mesothelioma/) - `s-Hertogenbosch, the Netherlands; 08 December 2021. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces significant progress in its two clinical programs in pancreatic cancer as well as the full recruitment of all patients in its pivotal Phase II/III study in mesothelioma. Based on a preliminary efficacy analysis of the
- [Proof-of-concept Phase I clinical trial started to assess the safety and efficacy of CD40 agonist mitazalimab in combination with MesoPher in patients with progressive metastatic pancreatic cancer](https://www.amphera.nl/proof-of-concept-phase-i-clinical-trial-started-to-assess-the-safety-and-efficacy-of-cd40-agonist-mitazalimab-in-combination-with-mesopher-in-patients-with-progressive-metastatic-pancreatic-cancer/) - The REACtiVe-2 trial will assess the safety and efficacy of CD40 agonist mitazalimab (Alligator Bioscience) in combination with MesoPher in patients with progressive metastatic pancreatic cancer. The first patient has been dosed in the phase I proof-of-concept trial that will enroll up to 18 patients. The investigator initiated trial will be performed at Erasmus Medical
- [Article on DENIM study in Translational Lung Cancer Research (TLCR)](https://www.amphera.nl/article-on-denim-study-in-translational-lung-cancer-research-tlcr/) - An article on the DENIM study was recently published in Translational Lung Cancer Research: http://tlcr.amegroups.com/article/view/29434
- [DC vaccination-αCD40 combination therapy improves survival of pancreatic tumour-bearing mice](https://www.amphera.nl/dc-vaccination-αcd40-combination-therapy-improves-survival-of-pancreatic-tumour-bearing-mice/) - MesoPher is a personalised DC therapy consisting of autologous DCs loaded with PheraLys, Amphera’s proprietary allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for mesothelioma, contains a broad repertoire of tumour-associated antigens, many of which are also present in pancreatic cancer and other cancers. Preclinical results showed that DCs loaded with mesothelioma cell lysate
- [DENIM study presented at IMIG2021](https://www.amphera.nl/denim-study-presented-at-imig2021/) - At the (virtual) 15th Meeting of the International Mesothelioma Interest Group (iMig2021), Bob Belderbos of Erasmus MC, The Netherlands presented a poster on the DENIM study. His contribution (P038) can be found here on p174.
- [DENIM study presented as clinical trial in progress at the virtual WCLC2020](https://www.amphera.nl/denim-study-presented-as-clinical-trial-in-progress-at-the-virtual-wclc2020/) - Dr Bob Belderbos presented the DENIM study as clinical trial in progress at the virtual WCLC2020. The title of his presentation was: P24.03 - A Multicenter Randomized Phase III Trial of Dendritic Cell Maintenance Therapy After Chemotherapy in Mesothelioma; Denim Trial. The abstract can be found here.
- [Prof. Casper van Eijck presents first results of REACTIVE study](https://www.amphera.nl/prof-casper-van-eijck-presents-first-results-of-reactive-study/) - In a news item and a YouTube video of the Survival with Pancreatic Cancer Foundation / Support Casper campaign, Prof. Casper van Eijck presented the first promising results of a clinical phase II trial with dendritic cell therapy (MesoPher) in resected pancreatic cancer (REACTIVE trial).
- [BLSF participates in Amphera B.V.](https://www.amphera.nl/blsf-participates-in-amphera-b-v/) - Amphera has found a new investor. We are proud to announce that Brabant Life Sciences Seed Fonds has decided to participate in Amphera B.V..
- [Amphera is awarded first Red MedTechVentures loan of 350.000 Euro](https://www.amphera.nl/amphera-is-awarded-first-red-medtechventures-loan-of-350-000-euro/) - RedMedTech Ventures is a support programme for Life Science & Health start-ups, funded by the provinces of Gelderland, Overijssel and Noord-Brabant. At the Health Valley Event 2014 on March 13, Amphera was awarded a loan of 350.000 Euro as one of the two first companies. CEO Ilona Enninga: ”Amphera is very happy with this loan.
- [EMA Orphan Designation granted](https://www.amphera.nl/ema-orphan-designation-granted/) - The European Commission granted orphan designation (EU/3/13/1229, 16 January 2014) to Amphera for her innovative immunotherapy for the treatment of malignant mesothelioma.
- [FDA Orphan Designation granted](https://www.amphera.nl/fda-orphan-designation-granted/) - On May 6, 2014 the FDA – the U.S. Food & Drug Administration – granted Amphera’s treatment of malignant mesothelioma Orphan Designation.
- [Amphera is moving to a new office](https://www.amphera.nl/amphera-is-moving-to-a-new-office/) - On June 20, 2014 we are moving. On this day it might be difficult to contact us. Our sincere apologies for this inconvenience. We hope and trust that on Monday, June 23 we will be fully operational again. The new address of Amphera is: Onderwijsboulevard 225 (which was 219) 5223 DE 's-Hertogenbosch Our mailing address,
- [Dendritic cell immunotherapy is safe and clinically active in mesothelioma](https://www.amphera.nl/dendritic-cell-immunotherapy-is-safe-and-clinically-active-in-mesothelioma/) - Amphera B.V. today announces the positive results of the clinical study with MesoPher in patients with malignant mesothelioma. Amphera B.V., a spin-off company of Erasmus MC, develops dendritic cell immunotherapies for malignant mesothelioma and other cancers. Malignant mesothelioma is a fatal cancer caused by inhalation of asbestos fibers. Researchers of Erasmus MC, The Netherlands have
- [Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer](https://www.amphera.nl/amphera-recruits-first-patients-to-phase-ii-study-of-mesopher-to-treat-pancreatic-cancer/) - Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy `s-Hertogenbosch, The Netherlands, 21 May 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, announces that it has recruited the first patients to a phase II study of MesoPher to treat pancreatic cancer. REACtiVe (Rotterdam pancrEAtic cancer Vaccination trial) is an open-label
- [Amphera wins top ten list of most groundbreaking innovations in science](https://www.amphera.nl/amphera-wins-top-ten-list-of-most-groundbreaking-innovations-in-science/) - Amphera is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer. As a result of the selection, Amphera will be able to pitch at the Global Entrepreneurship Summit (GES) and will be
- [Coverage of Amphera's press release in Scrip and BioWorld](https://www.amphera.nl/coverage-of-ampheras-press-release-in-scrip-and-bioworld/) - Scrip's John Davis wrote an article on Amphera: https://scrip.pharmaintelligence.informa.com/SC124930/Amphera-Gears-Up-To-Evaluate-Dendritic-Cells-For-Pleural-Mesothelioma Nuala Moran of BioWorld covered Amphera's press release as well: http://www.bioworld.com/content/amphera-taking-mesothelioma-dendritic-cell-vaccine
- [Amphera video interview at BIO-Europe Spring 2019](https://www.amphera.nl/amphera-video-interview-at-bio-europe-spring-2019/) - At BIO Europe Spring 2019 in Vienna, Rob Meijer was interviewed by Mike Ward - Informa on combination therapy of MesoPher and checkpoint inhibitors.
- [Amphera presents data of MesoPher and checkpoint inhibitor combination therapy to treat mesothelioma at AACR 2019](https://www.amphera.nl/amphera-presents-data-of-mesopher-and-checkpoint-inhibitor-combination-therapy-to-treat-mesothelioma-at-aacr-2019/) - New data suggests high level of disease control possible with combination of dendritic cell therapy and PD-1/PD-L1 checkpoint inhibitors `s-Hertogenbosch, The Netherlands, 3 April 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, presented data from patients that received a combination of its dendritic cell therapy product MesoPher with marketed
- [Amphera recruits first patients to pivotal phase II/III study of MesoPher to treat pleural mesothelioma](https://www.amphera.nl/amphera-recruits-first-patients-to-pivotal-phase-ii-iii-study-of-mesopher-to-treat-pleural-mesothelioma/) - Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy to treat an orphan-designated cancer `s-Hertogenbosch, The Netherlands, 18 March 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, announces that it has recruited the first patients to its pivotal phase II/III study of MesoPher to treat pleural mesothelioma, a rare cancer
- [National and regional newspapers in The Netherlands publish article on the MESOPEC study](https://www.amphera.nl/national-and-regional-newspapers-in-the-netherlands-publish-article-on-the-mesopec-study/) - On January 25, 2018 National and regional newspapers in The Netherlands published an article on the MESOPEC study. Investigator dr. Eva Madsen and a patient are interviewed. MESOPEC is a phase II study with MesoPher in peritoneal mesothelioma. The article (in Dutch) can be found on: https://www.ad.nl/wetenschap/veelbelovende-behandelmethode-tegen-asbestkanker~a900b9dc/
- [ZonMW Parel awarded to prof dr Joachim Aerts for his research on dendritic cell immunotherapy MesoPher for mesothelioma](https://www.amphera.nl/zonmw-parel-awarded-to-prof-dr-joachim-aerts-for-his-research-on-dendritic-cell-immunotherapy-mesopher-for-mesothelioma/) - On March 15, 2018 prof Joachim Aerts MD of Erasmus MC received a “Parel” (Pearl) from ZonMW for his research on dendritic cell immunotherapy MesoPher for mesothelioma. ZonMW is the The Netherlands Organisation for Health Research and Development. The Dutch patient association, Asbestslachtoffers Vereniging Nederland (AVN) and Amphera received an “Oorkonde” (certificate) for their contributions
- [Successful DENIM Consortium Meeting at CHRU Lille](https://www.amphera.nl/hello-world-7-2/) - On March 30 2018, the participants in the DENIM study held a consortium meeting at CHRU Lille in France. Prof Arnauld Scherpereel and his team hosted the meeting. All topics were discussed in a very constructive atmosphere.
- [Results Phase I/II study with MesoPher published in Clinical Cancer Research](https://www.amphera.nl/results-phase-i-ii-study-with-mesopher-published-in-clinical-cancer-research/) - Amphera is happy to announce that the results of our phase I/II study with MesoPher in mesothelioma are published in the February 2018 issue of Clinical Cancer Research.
- [World Cancer Day 2018 - Presentation of Prof dr Joachim Aerts on dendritic cell immunotherapy for mesothelioma](https://www.amphera.nl/hello-world-7-3/) - On World Cancer Day February 4 2018, KWF - Dutch Cancer Society - organized several activities to increase the awareness about cancer and its impact. Prof Joachim Aerts was one of the guests in live programs on the radio and internet. In his contribution, he discussed the results of the phase I/II studies with dendritic

## Pages

- [Home](https://www.amphera.nl/) - EMPOWERING DENDRITIC CELLS Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer. MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour
- [Cookie Policy (EU)](https://www.amphera.nl/cookie-policy-eu/)
- [News](https://www.amphera.nl/news-2/) - NEWS COVERAGE
- [PRIVACY POLICY](https://www.amphera.nl/privacy-policy/) - The information contained in this website is for general information purposes only. The information is provided by Amphera and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the
- [DISCLAIMER](https://www.amphera.nl/disclaimer/) - The information contained in this website is for general information purposes only. The information is provided by Amphera and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the
- [The principle](https://www.amphera.nl/the-principle/) - THE PRINCIPLE Dendritic Cells (DCs) capture, process, and present antigens to the immune system. Amphera ex vivo extracts and activates cancer patients’ own (monocyte derived) DCs enabling them to present tumour-associated antigens (TAAs) to the immune system. On returning the activated DCs to the patient, they migrate to the lymph nodes, where they induce an
- [About MesoPher](https://www.amphera.nl/about-mesopher/) - ABOUT MESOPHER MesoPher, Amphera’s lead product, is comprised of autologous DCs (i.e. from the patient) loaded with “PheraLys” – Amphera’s allogeneic lysate of mesothelioma cell lines. Dendritic cells can be generated ex vivo from monocytes obtained from the patient’s peripheral blood, outside the immunosuppressive environment. DCs can be loaded ex vivo with TAAs. These may
- [Publications](https://www.amphera.nl/publications/) - PUBLICATIONS Vroman, H. et al (2020). T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. Journal for ImmunoTherapy of Cancer 2020;8:e000251. Belderbos, R.A. et al (2020). Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Front Oncol. 2020 Jun 3;10:777. Belderbos, R.A. et al (2019). A multicenter, randomized, phase
- [Pleural mesothelioma](https://www.amphera.nl/pleural-mesothelioma-2/) - PLEURAL MESOTHELIOMA There is only one therapy approved for the treatment of malignant mesothelioma, a combination chemotherapy of pemetrexed and cisplatin. Median survival with the best standard of care is 12 months after diagnosis. For more information on pleural mesothelioma: cancer.org/cancer/malignant-mesothelioma.html kanker.nl/kankersoorten/mesothelioom/wat-is/mesothelioom-asbestkanker (Dutch) Pivotal phase II/III study Six mesothelioma referral centers in five European countries
- [Pipeline](https://www.amphera.nl/pipeline/) - PIPELINE MesoPher is a platform technology. Currently 3 clinical studies are ongoing. MesoPher is a platform technology. Currently 3 clinical studies are ongoing. INDICATIONS Pleural mesothelioma Pleural malignant mesothelioma is a cancer of the lining of the lungs. Pleural mesothelioma is caused by inhalation of asbestos fibers. In Western countries about 13.000 mesothelioma deaths are
- [Koen Bezemer, ATMP Manufacturing](https://www.amphera.nl/koen-bezemer-atmp-manufacturing/) - KOEN BEZEMER - ATMP MANUFACTURING Koen holds a bachelor degree in Biomolecular Medicine (University of Rotterdam) and a Post-Bachelor degree in Management (NCOI). Since 2010 and before joining Amphera, Koen was involved in Research & Development of MesoPher at Erasmus MC (including the early phase clinical trials), where he gained novel product expertise as well
- [Christine Mitchell – Quality Assurance](https://www.amphera.nl/christine-mitchell-quality-assurance/) - CHRISTINE MITCHELL – QUALITY ASSURANCE Christine graduated in the UK with a BSc (Honors) in Combined Studies (Biology and Chemistry). Christine has more than 30 years of experience in Quality Assurance, Safety Assessment within contract research organizations including: NOTOX BV, WIL Research BV and Charles River. During this period she also represented the industry within
- [Ilona Enninga, PhD - Chief Operations Officer](https://www.amphera.nl/ilona-enninga-phd-chief-operations-officer/) - ILONA ENNINGA PHD - CHIEF OPERATING OFFICER Ilona graduated (cum laude) in Biochemistry and Virology (University of Amsterdam) and has a PhD degree in Mutagenesis (Leiden University). Ilona is a board certified toxicologist and experienced operational manager, co-building NOTOX BV and being COO of NOTOX BV/ WIL Research Europe BV for more than 25 years.
- [Rob Meijer, Chief Executive Officer](https://www.amphera.nl/rob-meijer-chief-executive-officer/) - ROB MEIJER - CHIEF EXECUTIVE OFFICER Rob holds a degree in Industrial Engineering & Management (University of Twente) and a post-graduate Master Management Consulting (VU Amsterdam). Before joining Amphera, Rob worked for Hoechst Holland, Coopers & Lybrand/ PwC Consulting/ IBM Business Consulting Services and Meijer & Van der Ham Management Consultants. < back
- [Joachim Aerts, MD, PhD Medical Advisor](https://www.amphera.nl/joachim-aerts-md-phd-medical-advisor/) - PROF. JOACHIM AERTS MD PHD - MEDICAL ADVISOR Joachim Aerts is a board certified pulmonologist with broad research experience in immune-oncology. He has published over 200 peer-reviewed publications. Joachim is head of the department of Pulmonary Diseases at Erasmus MC in Rotterdam, the Netherlands. < back
- [About our company](https://www.amphera.nl/about-our-company/) - ABOUT OUR COMPANY Amphera B.V., established in December 2012, is a spin-off company from Erasmus MC. Amphera is located in ‘s-Hertogenbosch, The Netherlands. OUR TEAM Our multidisciplinary team.
- [Partners](https://www.amphera.nl/partners-2/) - PARTNERS Amphera cooperates with Erasmus MC, RedMedTech Discovery Fund and RVO INVESTORS Amphera’s major shareholders are Brabant Life Sciences Seed Fund (BLSF), De Mandemakers Groep, Lupus Ventures and Reggeborgh Medical.
- [Pancreatic cancer](https://www.amphera.nl/pancreatic-cancer-2/) - PANCREATIC CANCER Over 450,000 new cases of pancreatic cancer were diagnosed in 2018, with 430,000 deaths.1 Overall five-year survival rates for the disease in the U.S. are 9%.2 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries doi.org/10.3322/caac.21492 American Cancer Society. Cancer Facts & Figures 2019. Atlanta:American Cancer Society;
- [Peritoneal mesothelioma](https://www.amphera.nl/peritoneal-mesothelioma-2/) - PERITONEAL MESOTHELIOMA Peritoneal mesothelioma is a cancer of the peritoneum (the lining of the abdominal cavity, approximately 10% of all mesothelioma cases). Currently, surgery and chemotherapy are the standard of care. However, recurrence rates are high. For more information on peritoneal mesothelioma: cancer.org/cancer/malignant-mesothelioma.html kanker.nl/kankersoorten/mesothelioom/wat-is/mesothelioom-asbestkanker (Dutch) Phase II study Six mesothelioma referral centers in five European
- [CONTACT](https://www.amphera.nl/contact/) - Amphera Onderwijsboulevard 225 5223 DE ’s-Hertogenbosch The Netherlands Email: info@amphera.nl For navigation, please use the following address: Vlijmenseweg 1a, Den Bosch. BUSINESS DEVELOPMENT We would appreciate meeting you to discuss collaboration opportunities. Please contact Rob Meijer on info@amphera.nl.
- [test catagory posts](https://www.amphera.nl/test-catagory-posts/) - [display-posts category="Amphera news" include_date="true" date_format="F j, Y" posts_per_page="30"] [display-posts category="Coverage"]
- [news archive](https://www.amphera.nl/news-archive/) - [vc_row center_row=”yes” full_mobile_row=”yes” padding_top=”40″ padding_bottom=”80″][vc_column width=”2/3″ el_class=”latestnews”][vc_wp_posts title=”NEWS ARCHIVE” number=”100″ show_date=”1″][/vc_column][/vc_row]
- [terms of use](https://www.amphera.nl/terms-of-use/) - [vc_row center_row=”yes” full_mobile_row=”yes” padding_top=”40″ padding_bottom=”80″][vc_column][vc_column_text] Terms of use The information contained in this website is for general information purposes only. The information is provided by [business name] and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness,

## Categories

- [Amphera news](https://www.amphera.nl/category/amphera-news/)
- [Coverage](https://www.amphera.nl/category/coverage/)

## Tags

- [interview](https://www.amphera.nl/tag/interview/)
- [CEO](https://www.amphera.nl/tag/ceo/)
- [Informa](https://www.amphera.nl/tag/informa/)
- [BIO Europe](https://www.amphera.nl/tag/bio-europe/)
- [Vienna](https://www.amphera.nl/tag/vienna/)
- [pancreatic cancer](https://www.amphera.nl/tag/pancreatic-cancer/)
- [reactive](https://www.amphera.nl/tag/reactive/)
- [casper van eijck](https://www.amphera.nl/tag/casper-van-eijck/)